Estradiol News and Research

RSS

Estradiol is a sex hormone. Mislabelled the "female" hormone, it is also present in males; it represents the major estrogen in humans. Estradiol has not only a critical impact on reproductive and sexual functioning, but also affects other organs including the bones.

Telephone-based weight loss intervention is effective in breast cancer treatments

A series of simple telephone calls can make a profound difference in helping women to meet their treatment goals for breast cancer, according to a randomized trial of women who are also obese, published online today in Journal of Clinical Oncology by Dr. Pamela Goodwin of Mount Sinai Hospital and the Lunenfeld-Tanenbaum Research Institute.

20 Jun 2014

Childhood oestrogen may normalise thelarche in Turner syndrome

Treating girls with Turner syndrome with low-dose oestrogen from childhood results in earlier thelarche and a slower tempo of puberty, research shows.

16 Jun 2014

Estrogen therapy and venlafaxine treatment effective for hot flashes, night sweats

A new research study from Brigham and Women's Hospital (BWH) that compares low-dose oral estrogen and low-dose non-hormonal venlafaxine hydrochloride extended release (XR) to placebo were both found effective in reducing the number of hot flashes and night sweats reported by menopausal women.

27 May 2014

Antares Pharma reports total revenues of $5.2 million for first quarter 2014

Antares Pharma, Inc. today reported operating and financial results for the first quarter ended March 31, 2014.

9 May 2014

Studies demonstrate new approaches to treating and preventing Parkinson's disease

A trio of studies from the Perelman School of Medicine at the University of Pennsylvania demonstrate new approaches to understanding, treating and potentially staving off Parkinson's disease (PD). Studies show that factors such as estrogen exposure and statin use have an impact on the onset of Parkinson's disease.

29 Apr 2014

Antares Pharma reports total revenue of $4.7 million for fourth quarter 2013

Antares Pharma, Inc. today reported operating and financial results for the fourth quarter and full year ended December 31, 2013.

13 Mar 2014

Antares Pharma announces launch of OTREXUP to Dermatologists

Antares Pharma, Inc. today announced LEO Pharma's launch of OTREXUP to Dermatologists, the first U.S. Food and Drug Administration approved subcutaneous (SC) methotrexate (MTX) product for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.

10 Mar 2014

TherapeuticsMD's fourth quarter 2013 net revenue increases to $2.9 million

TherapeuticsMD, Inc., a women's healthcare company, today announced results for the three-month period and full-year ended December 31, 2013.

4 Mar 2014

More than 1/3 of women experience hot flashes for 10 years after menopause

A team of researchers from the Perelman School of Medicine at the University of Pennsylvania has found that moderate to severe hot flashes continue, on average, for nearly five years after menopause, and more than a third of women experience moderate/severe hot flashes for 10 years or more after menopause.

31 Jan 2014

Study points to gender-specific mechanisms of brain repair following oxygen deprivation

Physicians have long known that oxygen deprivation to the brain around the time of birth causes worse damage in boys than girls. Now a study by researchers from the Johns Hopkins Children’s Center conducted in mice reveals one possible reason behind this gender disparity and points to gender-specific mechanisms of brain repair following such injury.

31 Jan 2014

OASIS receives research award from MJFF to develop saliva-based, rapid test for Parkinson's detection, diagnosis

Oasis Diagnostics Corporation is the recipient of a research award from The Michael J. Fox Foundation for Parkinson's Research to validate OASIS' development of a non-invasive, saliva-based, rapid test for Parkinson's disease detection and diagnosis.

8 Jan 2014

Actavis' subsidiary files ANDA for generic version of NuvaRing

Actavis plc today confirmed that its subsidiary, Warner Chilcott Company LLC, has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Ethinyl Estradiol and Etonogestrel Vaginal Ring, 0.015 mg/24 hour and 0.12 mg/24 hour.

26 Dec 2013

Antares Pharma receives Notice of Allowance for new patent application on reconstitutable drugs

Antares Pharma, Inc. today announced that it has received a Notice of Allowance from the U.S. Patent Office for application 13/584,317. This application, along with U.S. Patent 8,251,947 granted in August of 2012, relate to Antares' injector technology for wet-dry injectable drugs such as lyophilized biologicals or peptide drugs that require dry storage to assure stability.

20 Dec 2013

Potential dual benefits to tackling LUTS progression risk factors

Research shows that several risk factors associated with Type 2 diabetes and cardiovascular disease also predict the progression of storage and voiding lower urinary tract symptoms in men, suggesting that targeting these could have multiple benefits.

16 Dec 2013

Population Council partners with USAID to introduce new line of contraceptive rings

The Population Council was awarded a cooperative agreement from the U.S. Agency for International Development's Office of Population and Reproductive Health, "Delivering a Family of Contraceptive Vaginal Rings." Included in this agreement is support for two innovative, Population Council-developed contraceptive vaginal rings: a one-year contraceptive vaginal ring that can be used by women to plan their pregnancies and a three-month vaginal ring that can be used by breastfeeding women.

10 Dec 2013

Estradiol News and Research

Further Reading

Telephone-based weight loss intervention is effective in breast cancer treatments

Childhood oestrogen may normalise thelarche in Turner syndrome

Estrogen therapy and venlafaxine treatment effective for hot flashes, night sweats

Antares Pharma reports total revenues of $5.2 million for first quarter 2014

Studies demonstrate new approaches to treating and preventing Parkinson's disease

Antares Pharma reports total revenue of $4.7 million for fourth quarter 2013

Antares Pharma announces launch of OTREXUP to Dermatologists

TherapeuticsMD's fourth quarter 2013 net revenue increases to $2.9 million

More than 1/3 of women experience hot flashes for 10 years after menopause

Study points to gender-specific mechanisms of brain repair following oxygen deprivation

OASIS receives research award from MJFF to develop saliva-based, rapid test for Parkinson's detection, diagnosis

Actavis' subsidiary files ANDA for generic version of NuvaRing

Antares Pharma receives Notice of Allowance for new patent application on reconstitutable drugs

Potential dual benefits to tackling LUTS progression risk factors

Population Council partners with USAID to introduce new line of contraceptive rings

New research shows that the brain can produce and release estrogen

Scientists study effect of diet complexity, estrogen hormone receptors on intestinal microbiota

Amneal to launch AB-rated generic for Loestrin 24 Fe

BRCA1/2 mutations may alter endometrial, ovarian function

Results of Phase 3 clinical trial of contraceptive vaginal ring presented by Population Council

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News